- Eagle Pharmaceuticals ( NASDAQ: EGRX ) is scheduled to announce Q3 earnings results on Monday, November 7th, before market open.
- The consensus EPS Estimate is $0.91 (+62.5% Y/Y) and the consensus Revenue Estimate is $62.08M (+55.8% Y/Y).
- Over the last 2 years, EGRX has beaten EPS estimates 38% of the time and has beaten revenue estimates 25% of the time.
- Over the last 3 months, EPS estimates have seen 0 upward revisions and 3 downward. Revenue estimates have seen 0 upward revisions and 3 downward.
For further details see:
Eagle Pharmaceuticals Q3 2022 Earnings Preview